Reply to F.E. Vera-Badillo et al

Affiliations

Comment

Jonathan E Rosenberg et al. J Clin Oncol. 2020.

. 2020 Feb 20;38(6):651-652.

doi: 10.1200/JCO.19.02830. Epub 2019 Dec 27.

¹ Jonathan E. Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY; and Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT.

No abstract available

Comment on

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Rosenberg JE, et al. J Clin Oncol. 2019 Oct 10;37(29):2592-2600. doi: 10.1200/JCO.19.01140. Epub 2019 Jul 29. J Clin Oncol. 2019. PMID: 31356140 Free PMC article. Clinical Trial.
Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity.
Vera-Badillo FE, Robinson AJ, Berman DM, Booth CM. Vera-Badillo FE, et al. J Clin Oncol. 2020 Feb 20;38(6):649-651. doi: 10.1200/JCO.19.02393. Epub 2019 Dec 27. J Clin Oncol. 2020. PMID: 31880965 No abstract available.